The ketamine enantiomer S-ketamine (esketamine) was recently approved by the FDA for the management of treatment-resistant depression.

Designed as a nasal spray, for use in combination with an oral antidepressant in patients with treatment-resistant depression, tight controls have been out in place in an effort to curb abuse.

See the full piece on Medical News Today.